2-Methylamino-propionic acid ethyl ester; hydrochloride | 2170123-35-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-Methylamino-propionic acid ethyl ester; hydrochloride
• 英文别名: Ethyl 2-(methylamino)propanoate hydrochloride；ethyl 2-(methylamino)propanoate;hydrochloride
• CAS: 2170123-35-8
• 化学式: C₆H₁₃NO₂*ClH
• 分子量: 167.636
• InChiKey: ONRCQWWOUUVQMT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.58
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  38.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-Methylamino-propionic acid ethyl ester; hydrochloride 在 盐酸 、 sodium nitrite 作用下， 生成 N-Nitroso-N-methyl-alanin-ethylester
  参考文献：
  名称：

  158.一些潜在的细胞毒性甲基亚硝胺

  摘要：

  DOI：

  10.1039/jr9630000846

文献信息

• [EN] FUSED PYRROLEDICARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] PYRROLEDICARBOXAMIDES FUSIONNÉS ET LEUR UTILISATION EN TANT QUE PRODUITS PHARMACEUTIQUES
  申请人：SANOFI SA

  公开号：WO2013113860A1

  公开（公告）日：2013-08-08

  The present invention relates to fused pyrroledicarboxamides of the formula (I), in which R1 to R9, X, m and n are as defined in the claims. The compounds of the formula (I) are inhibitors of the acid-sensitive potassium channel TASK-1 and suitable for the treatment of TASK-1 channel-mediated diseases such as arrhythmias, in particular atrial arrhythmias like atrial fibrillation or atrial flutter, and respiratory disorders, in particular sleep-related respiratory disorders like sleep apnea, for example.

  本发明涉及公式（I）中的融合吡咯二羧酰胺，其中R1至R9、X、m和n如权利要求中所定义。公式（I）化合物是酸敏感钾通道TASK-1的抑制剂，适用于治疗TASK-1通道介导的疾病，如心律失常，特别是心房心律失常，如心房颤动或心房扑动，以及呼吸系统疾病，特别是与睡眠相关的呼吸系统疾病，如睡眠呼吸暂停症等。
• Synthesis of novel 6,7-dihydro-5H-pyrimido[4,5-e][1,4]diazepin-8(9H)-ones
  作者：Jinbao Xiang、Xiaowei Hu、Qun Dang、Xu Bai

  DOI：10.1002/jhet.615

  日期：2011.9

  developed for the synthesis of 6,7‐dihydro‐5H‐pyrimido[4,5‐e][1,4]diazepin‐8(9H)‐one derivatives. The key to construct the pyrimido[4,5‐e][1,4]diazepine core is the intramolecular amidation of N‐((4‐amino‐6‐chloropyrimidin‐5‐yl)methyl)‐substituted amino acid esters. This methodology was validated through the preparation of 13 representative 6,7‐dihydro‐5H‐pyrimido[4,5‐e][1,4]diazepin‐8(9H)‐ones in moderate

  一种新方法是为6,7-二氢5的合成开发ħ嘧啶并[4,5- ë ] [1,4]二氮杂-8-（9 ħ） -酮衍生物。构造嘧啶并[4,5- e ] [1,4]二氮杂core核心的关键是N -（（4-氨基-6-氯嘧啶-5-5-基）甲基）取代的氨基酸酯的分子内酰胺化作用。这种方法是通过13代表6,7-二氢5的制备验证ħ嘧啶并[4,5- ë ] [1,4]二氮杂-8-（9 ħ） -酮在中度至良好的产率。J.杂环化​​学。（2011）。
• Fused Pyrroledicarboxamides and Their Use as Pharmaceuticals
  申请人：SANOFI

  公开号：US20160159793A1

  公开（公告）日：2016-06-09

  The present invention relates in fused pyrroledicarboxamides of the formula (I), in which R1 to R9, X, m and n are as defined in claims. The compounds of the formula (I) are inhibitors of the acid-sensitive potassium channel TASK-1 and suitable for the treatment of TASK-1 channel-mediated diseases such as arrhythmias, in particular atrial arrhythmias like atrial fibrillation or atrial flutter, and respiratory disorders, in particular sleep-related respiratory disorders like sleep apnea, for example.

  本发明涉及式(I)的融合吡咯二酰胺，其中R1至R9、X、m和n如权利要求中所定义。公式(I)化合物是酸敏感钾通道TASK-1的抑制剂，适用于治疗TASK-1通道介导的疾病，如心律失常，特别是房颤或心房扑动，以及呼吸系统疾病，特别是睡眠相关呼吸障碍，如睡眠呼吸暂停等。
• 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
  申请人：Hoffmann-La Roche Inc.

  公开号：US10233184B2

  公开（公告）日：2019-03-19

  The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

  本发明涉及式（I）化合物、 其中 R1、R2 和 R3 如本文所述，及其原药或药学上可接受的盐、对映体或非对映异构体，以及包括这些化合物的组合物和使用这些化合物的方法。
• FUSED PYRROLEDICARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS
  申请人：SANOFI

  公开号：EP2809669A1

  公开（公告）日：2014-12-10